Free Urgent Insider Catalyst Report For MNKD Available Here
Sequenom, Inc. (NASDAQ:SQNM) shares dropped 1.82% to $2.69. The company on Jan. 14 announced its wholly owned subsidiary, Sequenom Laboratories, entered into an agreement to offer access to its MaterniT21
PLUS laboratory-developed test to Mayo Medical Laboratories. Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal aneuploidies.
Free Urgent Insider Catalyst Report For SQNM Available Here
Additionally, the company on Jan. 8 announced that on January 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled “Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing,” invented by Drs. Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong.
Mast Therapeutics Inc(NYSEMKT:MSTX) shares gained 4.38% to $0.81. The company on Jan. 6 announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
]]>Free Urgent Insider Catalyst Report For SQNM Available Here
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares declined 2.40% to $3.66. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Free Urgent Insider Catalyst Report For ACHN Available Here
Athersys, Inc.(NASDAQ:ATHX) shares gained 3.32% to $4.05. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
Free Urgent Insider Catalyst Report For ATHX Available Here
Dendreon Corporation(NASDAQ:DNDN) shares increased 2.11% to $2.91. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company’s first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.
]]>